The SOPHiA DDM™ platform used by IHG PAS to advance its male infertility research
BOSTON and ROLLE, Switzerland, November 17, 2023 /CNW/ — SOPHiA GENETICA (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Institute of Human Genetics, Polish Academy of Sciences (IHG PAS), the leading genetic research center in Poland, is now available on the SOPHiA DDM™ platform. IHG PAS will use SOPHiA GENETICA to advance its research into rare diseases, in particular male fertility.
It is estimated that around one in six people worldwide will be affected by infertility in their lifetime.1 As a staple in the medical research community of Poland, IHG PAS specializes in several areas of research, including reproductive biology. When using the SOPHiA DDM™ platform, the Department of Reproductive Biology and Stem Cells of IHG PAS intends to deepen its research in the area of male infertility, through next generation sequencing (NGS) for the genetic evaluation of infertility.
“The research we do at IHG PAS is widely used across Poland due to our deep relationships with the surrounding medical community and our nearly 50-year history,” said Marta Olszewska, Assistant Professor, Head of the Sperm Genetics Research Team, IHG PAS. “With the implementation of the SOPHiA DDM™ platform, our team is now able to streamline their research and provide our partners with accelerated discoveries that can positively impact the understanding of infertility.”
IHG PAS will use the SOPHiA DDM™ Whole Exome Solution (WES), which is a next-generation sequencing (NGS)-based application that provides a streamlined end-to-end workflow, from sample to variant reporting, to accelerate research into hereditary diseases, including infertility. Using the SOPHiA DDM™ platform, IHG PAS will analyze results and simplify insights in an efficient time frame.
“The advanced analytical analysis provided by the SOPHiA DDM™ platform provides nightly WES analysis and has a rich knowledge base to help identify variants of interest associated with rare diseases.” said Kevin Puylaert, Managing Director, EMEA, SOPHiA GENETICA. “Furthermore, the decentralized The nature of the SOPHiA DDM™ platform creates collective intelligence from all platform users around the world and can help better inform researchers studying rare diseases, including IHG PAS researchers.”
With the SOPHiA DDM™ platform, IHG PAS will maintain full ownership of its database, supporting its research team as they continue to grow their expertise and develop their learnings.
For more information about SOPHiA GENETICAvisit SOPHiAGENETICS.COM or connect on X, LinkedIn, Facebook and Instagram.
About SOPHiA GENETICA
SOPHiA GENETICA (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal datasets and different diagnostic modalities. The SOPHiA DDM™ platform and related solutions, products and services are currently used by a broad network of hospital, laboratory and biopharmaceutical institutions around the world. For more information, visit SOPHiAGENETICS.COM or connect on Twitter, LinkedIn, Facebook and Instagram.Where others see data, we see answers.
SOPHiA GENETICA Products are for research use only and not for use in diagnostic procedures unless otherwise specified. The information contained in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a government regulatory body for different indications for use. Please contact support@sophiagenetics.com for product information appropriate for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical fact contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as management plans and objectives for future operations, are forward-looking. statements. Forward-looking statements are based on our management’s beliefs and assumptions and information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied by the forward-looking statements due to a variety of factors, including those described in our filings with the US Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions or circumstances on which such statements are based, unless required to do so. it by applicable legislation. law. No representation or warranty (express or implied) is made as to the accuracy of such forward-looking statements.
1 https://www.who.int/news/item/04-04-2023-1-in-6-people-globally-affected-by-infertility
View original content to download multimedia:https://www.prnewswire.com/news-releases/the-institute-of-human-genetics-polish-academy-of-sciences-ihg-pas-is-live-on-sophia-genetics-301992098.html
SOURCE SOPHiA GENETICA
© Canada Newswire, source Canada Newswire English
by 
